Blood test could predict who faces rapid kidney decline in diabetes

NCT ID NCT05198284

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial tests whether a blood-based test called KidneyIntelX can help doctors better manage patients with type 2 diabetes and early-stage chronic kidney disease. The test estimates the risk of rapid kidney function decline over five years. Researchers will see if using this test leads to more patients hitting treatment targets—like blood pressure, blood sugar, and protective medications—and whether it improves kidney health. The study includes 2,000 adults with type 2 diabetes and mild to moderate kidney impairment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
KidneyIntelX, a blood-based diagnostic test that estimates the risk of rapid kidney function decline in people with type 2 diabetes and chronic kidney disease.
What this could lead to
If effective, this test could help doctors identify high-risk patients earlier and tailor treatments to slow kidney damage, potentially preventing or delaying kidney failure.
What could go wrong
The trial is large but still early in assessing real-world impact. The test may not consistently change doctor decisions or improve patient outcomes, and results may vary across diverse populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE STAGE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mount Sinai Health System

    New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.